240 likes | 283 Views
Registering an experimental mycoinsecticide product for stored grain pest control in collaboration with CABI and commercial companies since 2003. Objectives include research, trials, and addressing concerns.
E N D
Bio-control of grain storage insect pests Registering a mycoinsecticide product for use in storage structures. Project Executive: Julie Flood Senior Users: Dick Shaw Senior Suppliers:Sean Murphy Project Manager: Bryony Taylor Date: 12 April 2010
Part A – Background (1)Executive Summary & Objectives Executive Summary. The project is to register an experimental mycoinsecticide product to control pests in stored grain. This builds on work done in two LINK projects since 2003 and is a collaboration largely between CABI and FERA and three commercial companies. The project is led by Exosect Ltd • Project Objectives. • To carry out necessary research work to meet requirements of the registration dossier. • To carry out large-scale trials to this purpose. • To address (e.g. by desk studies) likely concerns of registration authorities.
Part A – Background (2)Key Stakeholders and Beneficiaries • Stakeholders and Beneficiaries:- • Donor: Technology Strategy Board • End-users: Grain producers, storers and processers • Partners: FERA; Exosect Ltd; Sylvan Spawn Ltd; Connaught. • CABI Centre: Europe-UK Theme - ISM
Part B – Implementation (1)Proposed Organisation Structure • Corporate Management: Joan Kelley • Project Board:- • Project Executive: Julie Flood • Senior Users: Dick Shaw • Senior Suppliers: Sean Murphy • CABI Budget-holder: Sean MurphyNote that, if not the Project Executive, the CABI Budget-holder must have written confirmation from the Project Executive, and the Project Manager if required by Project Executive, prior to authorising payment. • Project Manager: Bryony Taylor • Team Managers: N/A
Part B – Implementation (4)Customer Acceptance Criteria The Technology Strategy Board accept that product registration is the objective, but that this objective will be abandoned if either the science or the market suggest that the product will not be successful. Abandonment will be an acceptable outcome.
Part B – Implementation (5)Project Exclusions & Interfaces • Exclusions No commitment is made to registering a product if the scientific results prove unsatisfactory or if the financial returns are not considered acceptable. • Interfaces • The industrial partners determine the business profitability during the course of the project.
Part B – Implementation (6)Key Constraints & Assumptions • Constraints • Limited budget. • Assumptions • Market parameters do not worsen • Timely release of funds • Partners cooperate and remain as functioning organisations • Do not lose skilled staff • Skilled staff are not deliberately removed from project
Part C – Reasons for CABI (1)Key Business Benefits - Strategic • Expected £133,000 funding for three yr project • The project will result in a product for which CABI will gain considerable recognition (plus a royalty share). • There would be considerable opportunities to widen the use of the product, globally • The project will utilise biopesticide experience and help maintain this expertise within CABI • Strengthening of partnerships (FERA; a biocontrol company; user and producer) • Assist in further development of Beauveria based products.
Part C – Reasons for CABI (2)Key Business Benefits – Financial(Externally funded Projects only)
Part D – Risks (1)Key Risks(for Collaborator, Security, Technical Risks, see next slides)
Part E - Dissemination & Impact (2)Impact of Project(Scientific, Technical, Commercial, Social, Environmental)
Part F – Reporting & Sign-off (2)Supporting Documentation As a minimum to accompany the completed PID: • Project Financial Analysis Extra supporting documentation may be provided: • Gantt Chart (or Log Frame) • Any other documentation as appropriate Please note that projects with an Intellectual Property Right (IPR) component require the contract to be submitted to PMG prior to signature.
Part F – Reporting & Sign-off (3)Authorisation • Project Executive / EMT: …………………………………………… • Date: ………………………………………………………….. • PMG Sign-off (Level 1 Projects) ………………………………………….. • Date: …………………………………………………………………………. • Approval of: • PID • Development of Business Plan • PMG Comments and/or Follow-on Actions: